Solar-Recur: A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Men with Biochemical Recurrence of Prostate Cancer
Solar-Stage: A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection
Curium U.S. invoice terms and conditions of sale
Nuclear medicine education
Welcome customers Thank you for visiting our Nuclear Medicine Education website. Through this website we strive to provide a robust variety of Continuing Education (CE) programs relevant to the Nuclear Medicine Technologist. All courses are structured in a self-paced learning format, conveniently accessible 24 hours a day, 7 days a week, and include course assessments […]
Überblick
Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.
Sodium Iodide I-123 Capsules
Ioflupane I 123 Injection
RadioMedix and Curium Announce copper Cu 64 dotatate injection Was Granted Priority Review by the U.S. FDA
RadioMedix and Curium Announce FDA Approval of Detectnet (copper Cu 64 dotatate injection) in the U.S.
Curium und RadioMedix geben eine exklusive Vereinbarung für die 64Cu-Dotatate-Entwicklung bekannt.
NRG and Curium Sign Multi-Year Isotope Production Contract
RadioMedix and Curium Announce FDA Filing of copper Cu 64 dotatate injection New Drug Application
Curium Announces Approval of PulmotechTM MAA (kit for the preparation of technetium Tc 99m albumin aggregated injection) by the U.S. Food and Drug Administration
Curium to Expand Noblesville Facility’s Workforce
Curium Acquires Austrian Radiopharmaceuticals Company IASON
Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency
Kooperation von Curium und ROTOP zur Versorgung von Patienten mit STRIASCANTM
Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial
Curium announces last patient enrolled in their Phase 1/2 SOLAR clinical trial imaging men with histologically-proven metastatic prostate cancer using copper Cu 64 PSMA I&T
Curium und PIUR IMAGING kündigen eine Partnerschaft für die Schilddrüsenbildgebung in Deutschland an, um tomographische 3D-Ultraschallösungen zu ermöglichen
Curium: erste kommerzielle dosen von PYLCLARI® in Deutschland verfügbar – ein innovativer 18F-PSMA PET tracer für patienten mit prostatakrebs
Curium Gibt Erste Kommerzielle Dosen von Pylclari® – ¹⁸F-PSMA PET Radiopharmazeutikum in Österreich Bekannt
Curium Expands Nuclear Medicine Offerings, Announces U.S. Availability of Xenon Xe 133 Gas
Curium enhances its position in the French PET market with the completion of the acquisition of Cyclopharma’s French commercial and manufacturing operations
Curium Acquires Finnish Radiopharmaceuticals Company MAP Medical Technologies Oy
Curium Announces Revised Pricing for Technescan MAG3TM (kit for the preparation of technetium Tc 99m mertiatide)
Curium Acquires Zevacor Molecular Strengthening Its PET Portfolio
Curium Announces Drug Master File and Active Substance Master File for Germanium-68 in the U.S. and Europe
Online Ordering (Dublin, Ireland)
Curium to become major player in the supply on non carrier added Lu-177
Nuclear Medicine Outlook: Proven Molybenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients
Investigator Initiated Studies
Curium’s Customers to benefit from Mo-99 Production restart
Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99
